Study Protocol: Traditional Chinese Medicine (TCM) Syndrome Differentiation for Heart Failure patients and its Implication for Long-term Therapeutic Outcome of Qiliqiangxin Capsules

Alice Yeuk Lan Leung
The University of Hong Kong School of Chinese Medicine

Hoiyong Chen
The University of Hong Kong School of Chinese Medicine

Zhenhua Jia
Hebei Yiling Hospital

Xinli Li
Nanjing Medical University affiliated Nanjing Hospital: Nanjing First Hospital

Jiangang Shen (✉️ shenjj@hkucc.hku.hk)
University of Hong Kong  https://orcid.org/0000-0003-4772-5300

Research

Keywords: Qiliqiangxin (QLQX) capsule, traditional Chinese medicine (TCM), TCM syndrome differentiation, syndrome, syndrome element, tongue diagnosis, syndrome questionnaire, chronic heart failure, treatment efficacy

DOI: https://doi.org/10.21203/rs.3.rs-727082/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Study Protocol: Traditional Chinese Medicine (TCM) Syndrome Differentiation for Heart Failure patients and its Implication for Long-term Therapeutic Outcomes of the Qiliqiangxin Capsules

Alice Yeuk Lan Leung¹, Hoiyong Chen¹, Zhenhua Jia²,³, Xinli Li⁴, Jiangang Shen¹*

¹School of Chinese Medicine, University of Hong Kong, Hong SAR, P.R. China
²National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, China
³Hebei Yiling Hospital, Key Disciplines of State Administration of TCM for Collateral Disease, Shijiazhuang, China
⁴Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing 210029, China

*To whom correspondence should be address:
Prof. Jiangang Shen: School of Chinese Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong; Tel: +852-3017 6429; Fax:+852-2168 4259
Email: shenjg@hku.hku.hk

Abstract

Background: Syndrome differentiation is a commonly used methodology and practice in Traditional Chinese Medicine (TCM) guiding the diagnosis and treatment of diseases including heart failure (HF). However, previous clinical trials seldom consider the impact of syndrome patterns on the outcome evaluation of TCM formulae. Qiliqiangxin (QLQX) capsule is a TCM formula with cardiotonic effect to improve the cardiovascular function for heart failure with proven efficacy from well-designed clinical trials. Though, there is no clinical trial with a large sample size and long assessment period that considers the relationship between TCM syndrome differentiation and the treatment efficacy of
QLQX. In the present study, we design a study protocol to evaluate the relationship between TCM syndrome differentiation and the severity of heart failure as well as its progression. Furthermore, we will evaluate the impact of the TCM syndrome patterns on the efficacy of QLQX in the outcome of heart failure.

Methods: This is a clinical study conducted in conjunction with an ongoing clinical trial (QUEST Study\(^1\)) to evaluate the efficacy of QLQX to improve the outcome of HF treatment through the assessment of morbidity and re-hospitalization, which involves over 100 hospitals in mainland China and Hong Kong SAR with 3,080 HF patients. Firstly, we will apply a modified TCM Questionnaire to collect the clinical manifestations of HF and acquire the tongue images of the patients to facilitate the syndrome differentiation. We will base on the “2014 Consensus from TCM experts on diagnosis and treatment of chronic heart failure” to evaluate the TCM syndromes for the patients. Secondly, we will investigate the characteristic of TCM syndrome distribution of HF patients and its correlation with the functional and biochemical data. Furthermore, we will evaluate the relationship between the TCM syndrome patterns and the efficacy of QLQX in the treatment of heart failure. Lastly, we will investigate the implication of tongue diagnosis in the severity and therapeutic outcome of HF.

Expect Outcomes: To our knowledge, this will be the latest and well-designed clinical trial to evaluate the rules of TCM syndrome differentiation in the progression and therapeutic outcome of HF patients.
We expect to obtain direct clinical evidence to verify the importance of TCM syndrome differentiation for the diagnosis and treatment of HF.

Trial Registration: The trial was registered at Chinese Clinical Trial Registry, http://www.chictr.org.cn. (Registration No.: ChiCTR1900021929); Date: 2019-03-16.

Keywords: Qiliqiangxin (QLQX) capsule, traditional Chinese medicine (TCM), TCM syndrome differentiation, syndrome, syndrome element, tongue diagnosis, syndrome questionnaire, chronic heart failure, treatment efficacy
Heart Failure (HF) is an end-stage cardiovascular condition characterized by structural or functional cardiac impairments of ventricular filling or blood ejection, leading to abnormal hemodynamics, activating neuro-hormones, and developing myocardial remodeling (1, 2). The typical clinical manifestations include shortage of breath, fatigue and ankle swelling, accompanied by peripheral edema and elevated jugular venous pressure, etc. (3, 4). HF is one of the leading causes of death globally (5). There are approximately 64.3 million patients with heart failure worldwide (6). In the US, there are around 5.7 million HF patients and it is estimated to reach 8 million HF patients in 2030, accounting for a 46% increase in prevalence (7). Around 30-40% of HF patients have a history of hospitalization due to HF, and the reported 5-year all-cause readmission, readmission for HF, and mortality rates are 80.4%, 42.3%, and 75.4% respectively (8, 9). Thus, HF becomes a major public health burden in human diseases.

Current therapeutic strategies for HF include the following catalogs: Using nitrates and hydralazine to resolve vasoconstriction; Using angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and mineralocorticoid antagonists (MRAs) to target neuro-
hormonal systems; Using Invabradine to target the sinus nodes discharge and slow down the heart rates for the HF patients with unsatisfactory results with beta-blocker; Using cardiac resynchronization therapy (CRT) targeted the sinus rhythm and implantable cardioverter-defibrillator (ICD) targeted patients with cardiac arrhythmia, etc. (5). Even with the advanced treatment approaches developed, the outcome of HF treatments is still unsatisfactory as the re-hospitalization of worsening heart failure and mortality remain high.

Traditional Chinese Medicine (TCM) formulae, including Qiliqiangxin, Nuanxin, Shencaotongmai, Yangxinkang, appears to be the effective adjunct therapies with conventional drugs to improve cardiac function of HF patients (10). According to the TCM theory of Collateral Disease, the heart-qi and/or heart-yang deficiency could induce blood stagnation and the disruption of body fluid metabolism (11). The HF-induced hemodynamic dysfunctions and edema could be attributed to the pathological status of heart-qi deficiency accompanied with blood stagnation and body fluid accumulation (12). Syndrome differentiation is a unique TCM diagnosis in guiding therapeutic strategies for heart failure. However, there is no standardized methodology for syndrome differentiation of heart failure (13-15). The diversities of syndromes lead to difficulties in drawing conclusive outcomes and therefore, hindering the development of TCM treatment for heart failure (16, 17). On the other hand, Tongue Diagnosis is
crucial for identifying syndromes and evaluating the therapeutic responses in TCM practice. Tongue
Diagnosis has been applied for different diseases such as metabolic syndrome, cancer, menstrual
clinical symptoms, etc. (18-21). Recent studies observed the correlation between tongue patterns and
risk factors of heart failure in dialysis patients (22-24). The tongue changes were also observed in heart
failure patients with normal ejection fraction (22-24). Whether heart failure patients have specific
tongue patterns remains unclear. Therefore, we design this study to explore the impacts of TCM
syndrome patterns and tongue features on cardiovascular functions and the therapeutic outcome of
heart failure.

Qiliqiangxin (QLQX) capsule is a patent TCM formula approved by China Food and Drug
Administration for chronic heart failure (25). QLQX capsule is extracted from 11 TCM herbs including
Astragali Radix, ginseng radix at rhizoma, aconite lateralis radix preparata, salvia miltiorrhizae radix
et rhizome, semen descurainiae lepidii, alismatis rhizome, polygonati odorati rhizome, cinnamomi
ramulus, carthami flos, periploca cortex, and citri reticulatae periarpium. Previous studies indicated
that: (1) QLQX could attenuate cardiac remodeling via activating peroxisome proliferator-activated
receptor-γ (PPAR-γ) and mTOR; (2) QLQX could prevent cardiomyocytes hypertrophy via activating
PGC-1α and downregulating MiR-199a-5p, etc. (26-30); 3) QLQX could improve ejection fraction
and attenuates the left ventricular remodeling via inhibitory effect of the renin-angiotensin-aldosterone system (RAAS) (31, 32); (4) QLQX could inhibit the myocardial inflammation and cardiomyocyte apoptosis to promote the proliferation of cardiomyocyte (33). A multi-center, randomized, double-blind and placebo-controlled clinical trial reported that QLQX, as an adjunct therapy, reduced the level of NT-proB-type natriuretic peptide (NT-proBNP) and improved the NYHA functions, left ventricular ejection fraction (LVEF), 6-min walking distance, quality of life and composite cardiac events in HF patients (34). Those studies suggest that QLQX is a promising TCM formula for HF patients. However, the efficacy of QLQX on hard endpoint incidents such as re-hospitalization of worsening HF and mortality is yet to be proven. Particularly, whether different TCM syndrome patterns impact the therapeutic outcomes of QLQX is unknown. As such, we have designed QUEST study (35) to explore the long-term efficacy of QLQX in addition to conventional heart failure treatment of CHF. The primary outcome will be the occurrence of the composite endpoint which is defined as either cardiovascular (CV) death or re-hospitalization due to the exacerbation of HF. The secondary outcome measures include the all-cause mortality, secondary endpoint events (treatment terminated due to worsening heart failure, successful resuscitation after cardiac arrest, malignant arrhythmia, non-fatal stroke), CV death and re-hospitalization due to worsening heart failure in patients with ischemic heart disease, and the level of Serum NT-proBNP. In the present study, we target to evaluate the impacts of
TCM syndrome differentiation on the disease progress of HF and the therapeutic outcome of QLQX.

The study is coached by three specific objectives to answer the following questions: 1) Whether TCM syndromes are associated with the severity of heart failure; 2) Whether different TCM syndrome patterns have different therapeutic outcomes in QLQX treatment for heart failure; and 3) Whether TCM tongue diagnostic characteristics could be an effective index for the severity of heart failure and the indication of the progression as well as the therapeutic outcomes.

Methods/Design

1. Patient Recruitment and Selection Criteria

Our study is conducted in conjunction with a multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven clinical study named the QUEST on chronic heart failure patients. This study is carried out in approximately 100 centers located in China and Hong Kong SAR. These centers are eligible hospitals or affiliated hospitals of the medical universities. The target number of patient recruitments will be 3,080, which is calculated according to the PARADIGM-HF study based on the cardiovascular death or hospitalization rate for heart failure (36). This is an event-driven study and all the recruited patients will remain in the study (whether taking the study drug or not) until the number of the primary endpoint events reaches the predicted target of 620 cases, or the study meets
the pre-defined efficacy or safety criteria assessed by the Clinical Event Adjudication Committee (CEAC).

Recruitment of patients is assessed according to the pre-defined inclusion and exclusion criteria of the QUEST study (Table 1). Recruited patients must be at least 18 years old, can fulfill all the inclusion criteria including the NT-proBNP, LVEF, NYHA cardiac functional grading, and the standardized drug treatment for at least 2 weeks prior to enrollment, etc., and not meeting any exclusion criterion.

**Table 1. Inclusion and Exclusion Criteria**

| Inclusion criteria: |
|--------------------|
| 1) Provision of signed informed consent prior to any study specific procedures; |
| 2) Male or female, aged ≥18 years at the time of consent; |
| 3) Established documented diagnosis of heart failure for at least three months ago according to “Chinese Heart Failure Diagnosis and Treatment Guideline” issued by the Chinese Medical Association Cardiovascular Branch. |
| 4) Left ventricular ejection fraction (LVEF) ≤40% (echocardiogram, radionuclide, ventriculogram, contrast angiography or cardiac MRI); |
| 5) NYHA cardiac functional grading II to III, with stable clinical symptoms; including those diagnosed as grade IV within 2 weeks before enrollment; |
| 6) Serum NT-proBNP ≥ 450pg/ml; |
| 7) Those who have received standardized baseline treatment regimens without doses adjusted and given intravenously for at least two weeks prior to enrollment; standardized drug treatment includes: angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) or angiotensin receptor neprilysin inhibitor (ARNI), beta blocker, and aldosterone receptor antagonist (the optimal therapeutic dose should be achieved, except for contraindications or intolerance); |
Exclusion criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled
1) Heart failure caused by valvular disease, congenital heart disease, pericardial disease, arrhythmia or non-cardiogenic disease, or caused by vital organ failure (such as renal, hepatic failure, etc.); and right heart failure caused by pulmonary or other definite causes; and acute heart failure;
2) Coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or cardiac synchronization therapy planned to undergo after randomization, or had received cardiac resynchronization therapy prior to enrolment;
3) Any condition outside the CV diseases such as but not limited to malignant tumor, severe mental illness, hematopoietic diseases, neuroendocrine system disease, liver transaminase and alkaline phosphatase ≥ 3 x upper limit of normal (ULN), abnormal renal function serum creatinine > 2 mg/dl (176.82 umol/L), potassium >5.5mmol/L;
4) Patient with left ventricular outflow tract obstruction, myocarditis, aortic aneurysm, aortic dissection, or obvious hemodynamic changes caused by unrepaird valve;
5) Cardiogenic shock, uncontrollable malignant arrhythmia, sinus or atroventricular block at second degree type II or above without pacemaker treatment, progressive unstable angina pectoris or acute myocardial infarction;
6) Uncontrolled hypertension systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood pressure (DBP) ≥ 110mmHg; or SBP < 90mmHg and/or DBP <60mmHg;
7) Participation in another clinical study with an IP during the last month prior to enrolment;
8) Women of child-bearing potential (i.e., those who are not chemically or surgically sterilized or who are not post-menopausal) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator, from the time of signing the informed consent throughout the study and 4 weeks thereafter, OR women who have a positive pregnancy test at enrolment or randomization OR women who are breast-feeding;
9) Allergic constitution; known to be allergic to research drug;
10) Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures or any conditions may render the patient unable to complete the study.

Before the recruitment, patients must be “clinically stable” by receiving at least two weeks of standardized medication treatment according to the local treatment guideline for heart failure with
fixed drug type and dosage, as well as have not taken any intravenous anti-HF drug nor oral TCM medication with similar composition as the QLQX capsules. Once the patients are clinically stable, they will be assigned to the QLQX group or the control group in a ratio of 1-to-1 through the double-blind computerized randomize allocation. The patient will be given either QLQX capsules or placebo capsules during the assessment period in addition to their standard treatment for heart failure following the guidelines for diagnosis and treatment of HF in China 2018 (25) or local guideline. The QLQX capsules and placebo are identical in size and shape. The dosage used in this study is 4 capsules of QLQX or placebo 3 times daily. During the assessment period, patients should not take any TCM or herbs which have similar contents to the QLQX capsule.

The entire study will last for approximately 36 months with the first 24 months as the recruitment period. The study will be terminated once the last patient has finished the 12-months assessment. Once recruited, the patient is required to visit the hospitals for efficacy and safety assessment according to the study schedule. All patients are required to sign the Informed Consent Form before the recruitment. For each visit, the patient will be assessed by the researchers/physician. A range of clinical information and parameters will be collected and tests will be performed for the assessment of TCM syndrome, the treatment efficacy, and safety including laboratory and ECG results, etc. The assessment of safety of
this study will base on the reporting of the adverse events, SAEs, and laboratory abnormalities, which are closely monitored by the Data Safety Monitoring Committee (DSMC). Two interim efficacy analyses will be conducted when 1/2 and 2/3 primary endpoint events (i.e. around 310 and 414 patients respectively) are gathered. Patients are allowed to withdraw from the study for any reason but the reason is required to be recorded in the case report form. If the patient has an intolerable adverse event that is related to the study drug based on the researcher’s judgment, the patient should immediately discontinue the treatment with the study drug. The study flowchart is shown in Fig. 1.

Fig. 1 Study Flow Chart

- The pilot study for SDQHF assessment will be at least 342 questionnaires
- A preplanned interim analysis will be conducted to access efficacy and safety
- The analysis on TCM syndrome differentiation will base on the interim analysis and/or the termination of the study

Regimen: The guidelines for diagnosis and treatment of HF in China (2018 Edition) Standardized medical treatment of heart failure + QXQX/Placebo 4 capsules TID

1. Physical examination, CBC, Urine test, biochemical test & ECG parameters will be performed and assessed in the follow-up study visit
2. Endpoint Event, Adverse Event, Serious/Adverse Event (except for Visit 1)
3. SDQHF: Syndrome Diagnosis Questionnaire for heart failure
2. TCM Syndrome Diagnosis Questionnaire for Heart Failure (SDQHF)

To collect clinical information for TCM syndrome differentiation, a specialized TCM Syndrome Diagnosis Questionnaire for Heart Failure (SDQHF) is developed according to the TCM syndrome scales for heart failure reported by previous studies (37-40). The clinical manifestation including the signs and symptoms of heart failure diagnosis which are described according to the “2012 Guiding Principles for Clinical Study on New Drug for Use in Traditional Chinese Medicine”, “2014 Consensus from TCM experts on diagnosis and treatment of chronic heart failure”, “2017 Guideline for TCM Diagnosis and Treatment of Heart Failure (Chronic Heart Failure)” (16, 41, 42).

In the SDQHF, there are 36 closed-ended items and each item is given a ranked scale with simple descriptions to indicate the features of the severity or frequency of signs or symptoms. These 36 items are carefully considered to incorporate the major and concomitant signs/symptoms which are essential for the diagnosis of HF and the TCM syndrome differentiation. The descriptive scale per item is clearly defined and the scales were input by a group of experienced clinical experts and physicians. The SDQHF has gone through the review and pre-pilot testing by 20 subject matter experts including physicians and TCM practitioners.
The 36-items are divided into several dimensions including major signs and symptoms of heart failure, cold and heat characteristics, perspiration, head and general body condition, diet, etc. to facilitate the differentiation of heart failure and TCM syndrome. The terminologies used are specially considered to avoid jargon so that the questionnaire can be easily understood by the researchers/physicians and the patients. It will be an interviewer-administered questionnaire so that unclear questions can be clarified to the patients and ensure patients answer all the questions. The first 31 items in the SDQHF are required to be answered by the patients, and the last 5 items about the physical signs of the patients should be determined by the physician/researcher based on their observation of the patients. The list of 36-items in SDQHF is shown in Table 1.

Table 1. The list of 36-items in the TCM Symptom Diagnosis Questionnaire for Heart Failure (SDQHF)

| 1. Palpitations                                      | 10. Coughing out of Phlegm | 19. Cold Sweat                        | 28. Constipation |
|-----------------------------------------------------|-----------------------------|--------------------------------------|------------------|
| 2. Chest Tightness                                   | 11. Color of phlegm         | 20. Fear of cold                      | 29. Diarrhea     |
| 3. Precordial pain                                   | 12. Texture of phlegm       | 21. Coldness feeling in upper or lower limbs | 30. Frequency of urination |
| 4. Dizziness                                         | 13. Feeling fullness in chest/abdomen | 22. Feeling heat in 5 centers        | 31. Amount of urination |
| 5. Shortness of breath                               | 14. Hypochondriac pain or feeling of distension | 23. Appetite                      | 32. Distension of jugular vein |
| 6. Gasp for breath                                   | 15. Edema                   | 24. Sense of thirstiness              | 33. Cyanosis of face and lips |
| 7. Posture                                           | 16. Tiredness               | 25. Loss of sleep/insomnia           | 34. Color of face/complexion |
| 8. Coughing                                          | 17. Sweating at daytime     | 26. Dreaming                         | 35. Color of lips |
All enrolled patients are required to complete this questionnaire in a total of 6 specific study visits to the hospitals (i.e. Visit 1 at (Day 0), Visit 2(1M), Visit 3(3M), Visit 6(12M), Visit 10(24M) and Visit 14(36M)/EOS). The visit schedule and list of parameters are shown in Table 2. For each scheduled visit, the physician/researcher will conduct a face-to-face interview with the patient to go through this survey questionnaire. The entire interview process will last for approximately 8 to 10 minutes. The data collected will be first recorded manually in the paper SDQHF and then input into the Epidata software(43) which is the centralized database for the collection of research data from the QUEST study.

### Table 2. Planned visits and parameters

| Visit Schedule | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | UNS | EOS |
|----------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|-----|-----|
| Day/Month      | Day0 | 1M | 3M | 6M | 9M | 12M | 15M | 18M | 21M | 24M | 27M | 30M | 33M | 36M |       |     |
| -14            | x   | n3 | n3 | n7 | n7 | n7 | n7 | n7 | n7 | n7 | n7 | n7 | n7 | n7 | =2wks |     |
| Informed Consent |    | x  |    |    |    |    |    |    |    |    |    |    |    |    |       |     |
| Inclusion/Exclusion criteria | x |    |    |    |    |    |    |    |    |    |    |    |    |    |       |     |
| Randomization  | x  |    |    |    |    |    |    |    |    |    |    |    |    |    |       |     |
| General data and medical history | x |    |    |    |    |    |    |    |    |    |    |    |    |    |       |     |
| Medical history of HF | x |    |    |    |    |    |    |    |    |    |    |    |    |    |       |     |
| Medical history of CV Diseases | x |    |    |    |    |    |    |    |    |    |    |    |    |    |       |     |
| Physical examination | x | x₁ | x₁ | x₁ | x₁ | x | x₁ | x₁ | x₁ | x₁ | x₁ | x₁ | x₁ | x₁ | (x) | x  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|-----------------|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart failure medications | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Medications of other CVD | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Other medications | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| TCM Syndrome Diagnosis | x | x | x | x | x | x | (x) x |
| Questionnaire (SDQHF) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tongue Image Acquisition | x | x | x | x | x | x | x | x | x | x | (x) x |
| Echocardiogram | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Pregnancy Tests | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Blood/urine routine test | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Biochemical test | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| 12-lead ECG | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Serum NT-proBNP at local laboratory | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Dispensing IP | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Returning IP for accountability | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Endpoint Event | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Adverse Event | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |
| Serious Adverse Event | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | (x) x |

221  • X1 Simplified physical examination
222  • x* Cardiac ultrasound and 12-lead ECG within the first 6 months of enrollment
223  • UNS (unplanned visit): (x) The marked item is optional and performed according to the judgment of researchers
224  • EOS (final visit): Make arrangement according to the study end time (if there is a visit within one month before the end of study, it is regarded as a final visit, but needs to be supplemented with the items required completely)
225  • Pregnancy test is only applicable to women of childbearing age (if the urine pregnancy test is positive, it must be confirmed by serum pregnancy test).
226
227
228
229  3. TCM syndrome differentiation
230  According to the “2014 Consensus from TCM experts on diagnosis and treatment of chronic heart failure” (17), there are 3 major types of TCM syndrome for heart failure: 1) qi-deficiency with blood stasis syndrome; 2) qi-yin deficiency with blood stasis syndrome; 3) yang-qi deficiency with blood stasis syndrome;
stasis syndrome, and each can be associated with the phlegm-retention syndrome. These syndromes are comprised of a combination of 2-4 syndrome elements including 1) qi-deficiency; 2) yin-deficiency, 3) yang-deficiency; 4) blood stasis and 5) phlegm-retention. The list of clinical manifestations including signs and symptoms, pulse, and tongue features of the 3 TCM syndrome types are shown in Fig. 2. The 5 syndrome elements with 3 syndrome types indicated in this guideline are impeccably matched with the TCM Theory of Collateral Disease for heart failure.

**Fig. 2** Diagnosis and TCM Syndrome Differentiation for Heart Failure according to the “2014 Consensus from TCM experts on diagnosis and treatment of chronic heart failure”

A scoring model for syndrome differentiation is developed with reference to the criteria listed in Fig.2 and the TCM theories. The output from the scoring model will be the type of TCM syndrome and the
level of severity of heart failure patients at a specific stage of the disease. The output will be used for further analysis on the correlation of syndrome differentiation to the biomedical indicators, the severity of HF, and the therapeutic outcome of QLQX capsules.

4. Correlation analysis of TCM syndrome patterns and the therapeutic outcome of QLQX in CHF

Our primary objective is to explore the implication of TCM syndrome to the severity of heart failure and the therapeutic outcome of QLQX capsules. We hypothesize that the efficacy of QLQX Capsule on heart failure could be related to the clinical syndrome patterns in TCM diagnosis and likely be favorable to the patients with qi-deficiency with blood stasis and yang-qi deficiency with blood stasis.

The efficacy of QLQX capsule will be evaluated with reference to the “2012 Guiding Principles for Clinical Study on New Drug for Use in Traditional Chinese Medicine”. We will evaluate the correlation between TCM syndrome patterns and the severity of heart failure the re-hospitalization rates and mortality. The distribution of TCM syndrome will also be evaluated by NYHA classification, results from an electrocardiogram (ECG), cardiac ultrasound interpretation, and biochemical parameters from routine blood test such as NT-proBNP, urine test, etc. Other outcomes include: 1)
the distribution of TCM syndrome patterns in heart failure patients; 2) the correlation between TCM syndrome patterns and the severity of heart failure and 3) the dynamic changes between biomedical parameters and the TCM syndrome patterns of heart failure, etc.

5. Correlation of tongue features and the severity of HF and therapeutic outcome of QLQX

Tongue images of the patients will be acquired as part of the TCM Syndrome Diagnosis Questionnaire for Heart Failure (SDQHF) during the study visit. To ensure the quality and consistency of tongue photos from all clinical centers/hospitals, all researchers/physicians are properly trained according to the Standard Operation Procedures (SOP), and are provided with a standardized image acquisition device to capture the tongue image. The SOP includes the schedule of the study visit, the procedures for completing the SDQHF, and the criteria for capturing the tongue image such as the lighting requirement, camera mode (i.e. normal mode, no flashes, etc.), the posture of the tongue, and the tongue area to be included in the image, as well as the prerequisite requirements such as no intake of food or drinks that will stain the tongue coating on the day of the study visit. All tongue images should be sent to the central tongue image database via email with an indication of the patient number and the date of study visit.
We will set up a team of 4 TCM practitioners with 3 to 30 years of clinical experience to evaluate the tongue images. The identifiers and possible values for tongue analysis include the tongue color, tongue shape, tongue coating proper and its color, tongue coating distribution, appearance and location of ecchymosis, etc. Tongue images that fail to meet the SOP requirement will be excluded from the analysis. A 4-stage decision flow is designed for the review and analysis of tongue images: 1) direct confirmation if consistent interpretation and diagnosis from the first three TCM practitioners; 2) if consistent results are identical from 2 TCM practitioners but different diagnosis from the 3rd one, take the result from the majority; 3) if the interpretation and diagnostic results from all 3 TCM practitioners are different, will involve the 4th TCM practitioner with over 30 years of clinical experience to judge the syndrome type with the clinical information collected from the SDQHF; and finally, 4) if the image is determined as not in good quality for drawing the conclusion after reviewed by the separate TCM practitioner and professor, that tongue image will be excluded from the study.

Outcomes of the tongue analysis include 1) determination of the TCM syndrome differentiation of patients throughout the assessment period with the clinical information collected through the SDQHF; 2) tongue features in heart failure patients in accordance to the TCM syndrome, NYHA classification, and other biomedical data; 3) dynamic patterns of tongue condition in relation to the treatment efficacy and other biomedical indicators.
6. Data Management

The patient’s demographic data and all clinical data will be recorded and kept in the physical medical record folder during each study visit. The data will then be input into the Epidata software for centralization of all research data and all the tongue images will be kept in a separate centralized image database. The data management process will be complied with the regulatory requirements of Clinical Trial Quality Management Regulations and Clinical Trial Data Management Work Technical Guidelines to ensure the authenticity, integrality, accuracy, and traceability of data.

7. Sample size estimations

This study is benchmarked with the QUEST study in which 3080 patients will be enrolled in over 100 centers (1540 patients per group) and followed up for at least 12 months. The sample size was estimated referring to the PARADIGM-HF study (44). For QUEST study, the estimated incidence of cardiovascular death and hospitalization for heart failure is 25% in all patients receiving basic treatment + placebo group within 36 months of follow-up and 20% with those receiving basic treatment + QLQX Capsule group. The random distribution ratio is 1:1 between the study group and the control group. With the consumption of type I error in the interim analysis, $\alpha$ is adjusted to unilateral 0.02314. The sample size is the number of cases with composite endpoints events. Thus, 620
composite endpoint events are expected for the QUEST study to provide 80% power of test ($\beta = 0.2$),
and the 20% risk can be reduced in the study group by the log-rank test.

For the current study, a pilot test with at least 342 patients will be conducted to evaluate the
acceptability, reliability, and validity of the questionnaire. The number of patients for pilot testing is
calculated based on the confidence level of 95%, population size of 3,080, and 5% margin of error
for this 36-item questionnaire.

8. Data analysis and statistic methodology

Analysis of the TCM Questionnaire will be performed with the SPSS statistical software package,
version SPSS 24.0 (Chicago, IL, USA). Data will be presented by Mean±S.D. Principal Component
Analysis (PCA) will be applied to the questionnaire to examine the factor structure. Logistic regression
analysis will be used to evaluate the capability of SDQHF to diagnose the severity of HF from a
functional perspective. Pearson’s correlation coefficient will be used to determine the existence of
correlations between TCM syndrome differentiation and various parameters such as treatment efficacy,
NT-proBNP, NYHA classification, etc. An independent t-test will be used to compare quantitative
variables for the two-group designed study. Fisher’s Exact test and the chi-squared test will be applied
to compare categorical variables between groups. Multiple groups designed data will be analyzed by
two-way ANOVA.

Discussion

In TCM, the syndrome pattern is a vital component in both diagnosis and treatment of disease.
Syndrome elements, syndromes, phenotypic features, as well as disease, form an integral process in
the diagnostic path. However, due to the lack of standardization of syndromes, many diversified
syndrome types were found in previous studies, leading to difficulties in drawing sound conclusive
outcomes and thus, hindering research development (13-17). It is crucial to have an end-to-end
approach with a clear and definitive set of syndromes for heart failure study. The present study will
focus on the objective and quantitative syndrome diagnosis criteria for heart failure, the scoring model
of the SDQHF, and the establishment of the tongue image database. For the TCM syndrome pattern
recognition, we aim to develop a scoring system to catalog the syndrome differentiation from the signs
and symptoms in the questionnaire with reference to the guideline and consensus including the “2012
Guiding Principles for Clinical Study on New Drug for Use in Traditional Chinese Medicine”, “2014
Consensus from TCM experts on diagnosis and treatment of chronic heart failure”, and “2017
Guideline for TCM Diagnosis and Treatment of Heart Failure (Chronic Heart Failure)”. We expect the
development of SDQHF and the scoring model could establish a solid ground for syndrome
differentiation of heart failure and to facilitate the evaluation of the efficacy of the QLQX Capsule.
With the large-scale clinical trial and multiple level evaluations, we could provide an example to
resolve the unanswered question of whether the evidence-based clinical trials should consider the
potential influence on different TCM syndrome differentiation patterns on disease progress and
therapeutic outcome. This may enable the paradigm shift from reactive to predictive, preventive, and
personalized care through the application of the TCM syndrome differentiation.

In terms of operational issues, quality control is one of the major challenges for such large-scale
clinical studies involving over 100 clinical centers and more than 300 researchers/physicians in China
and Hong Kong. We have established standardized operating procedure (SOP) and provided extensive
training to all researchers/physicians prior to the patient recruitments. With the onset, supplementary
training and continuous review, we could ensure proper execution of SOP to secure the quality of data
collection. Tongue image acquisition is one of the critical issues for quality control. As such, we
provided an imaging capturing device of the same model to each clinical center and trained all the
researchers/physicians on how to properly acquire the tongue image, including the camera settings,
the lighting requirement, and other pre-requisite requirements for patients prior to the photo-taking,
etc. To ensure the image quality, we have a constant quality check on all tongue photos so that feedback
for improvement could be provided to the researchers/physicians on a timely basis. Thus, the quality
of tongue images could meet our requirement for the analysis of tongue features and patterns of heart
failure. We will also put efforts into patient communication to ensure all patients have a thorough
understanding of the trial so that they can strictly follow through the requirement and attend all
scheduled visits. With the high standard and high-quality clinical trial, we expect to achieve following
outcomes: (1) To verify that QLQX could be an adjunct therapy with conventional treatment to reduce
the mortality and re-hospitalization with worsening heart failure in the QUEST study. (2) To confirm
whether different TCM syndrome patterns and tongue characteristics would be associated with the
severity of heart failure and the therapeutic efficacy of QLQX on chronic heart failure patients.

Conclusion
To our knowledge, this study is a high standard designed, multi-center, randomized, double-blind,
parallel-group, placebo-controlled clinical trial with large scale subjects to verify the impacts of TCM
syndrome patterns on the severity of heart failure and the therapeutic outcome of Chinese medicine
formula. Furthermore, it may very well be the largest cohort clinical trial with long follow-up period
and hard endpoints to evaluate the long-term efficacy and safety of TCM formula in the treatment of
chronic heart failure.

Trial status
At the time of manuscript submission, the patient recruitment for the trial has just finished and we are now in the assessment period.

**List of abbreviations**

- 6MWD: 6-min Walking Distance
- CHF: chronic heart failure
- HF: heart failure
- NYHA: New York Heart Association
- QLQX: Qiliqiangxin Capsule
- LVMi: Left ventricular mass index
- LVEF: Left ventricular ejection fraction
- TCM: Traditional Chinese Medicine
- SDQHF: Syndrome Diagnosis Questionnaire for heart failure
- NT-proBNP: NT-proB-type Natriuertic Peptide
- SOP: Standard Operating Procedures
Declarations

**Ethics approval and consent to participate**

All participating centers must obtain approval from appropriate independent ethics committees or institutional review boards (Approved No. of ethic committee: 2018-SR-275). The study is conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. This study is conducted in conjunction with a current trial which is registered at [http://www.chictr.org.cn-ChiCTR1900021929](http://www.chictr.org.cn-ChiCTR1900021929). All participants must give written informed consent which should be acquired after a sufficient and detailed explanation to the research situation (including confidentiality, risk and benefits, the purpose of the study, etc.). For Hong Kong, the clinical trial is approved by the Department of Health with Certificate For Clinical Trial and Medicinal Test (Certificate No. CTMT-00008).

**Consent for publication**

Not applicable.

**Availability of data and materials**

Not applicable.

**Funding**

This study is conducted in conjunction with a current study (QUEST). QUEST is funded by National Key Technologies R&D Program, Modernization of Traditional Chinese Medicine of Ministry of Science and Technology of People’s Republic of China (Project No. 2017YFC1700501, 2017YFC1700505) and the Major Program of the National Natural Science Foundation of China (81730106). Qiliangxin capsules and the matching placebos are provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, People’s Republic of China).

The funding sources have not involved in the study design, data collection, analysis, interpretation of data and writing the manuscript.

**Competing interest**

The design of the study, data collection, data analysis and interpretation are independent to the funding body.

All executive committee members of QUEST study have received consulting fees as well as travel and research support in the planning and conduct of the QUEST study. The authors declare that they have no other conflict of interest to disclose.
**Author’s contribution**

YLL participated in the design of the research protocol and drafted the manuscript. JJS contributed to the conception and design of the research protocols. JJS also performed a critical revision of the manuscript for important intellectual content. HYC provided major revisions to the manuscript. ZHJ contributed to obtaining funding and the contact with multi-center. LXX contributed to the conception, design of the research protocols of the QUEST study. All authors read and approved the final manuscript.

**Acknowledgements**

We gratefully acknowledge the contributions of the sites and all participants in this study. We also thank Mr. Gao Wei for managing the QUEST study and provides support on all the logistics.
References:

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey JDE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239.

2. Ambrosy AP, Fonarow GC, Gheorghiade M, Butler J, Chioncel O, Greene SJ, et al. The Global Health and Economic Burden of Hospitalizations for Heart Failure: Lessons Learned From Hospitalized Heart Failure Registries. J Am Coll Cardiol. 2014;63(12):1123-33.

3. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res. 2017;121(6):677-94.

4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia polska (1957). 2016;74(10):1037-147.

5. Pellicori P, Khan MJ, Graham FJ, Cleland JGF. New perspectives and future directions in the treatment of heart failure. Heart Fail Rev. 2020;25(1):147-59.

6. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-56.

7. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11.

8. Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics. 2020;38(11):1219-36.

9. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368-76.

10. Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese Medicine for Cardiovascular Disease Evidence and Potential Mechanisms. Journal of the American College of Cardiology. 2017;69(24):2952-66.

11. Wu Y-L. Collateral Disease Theory in Practice: People's Medical Publishing House; 2008.

12. Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13(1):28-35.

13. Yang M, Cao X. Research Progress on Objective Indexes of TCM Syndrome Types of Congestive Heart Failure. Modern Journal of Integrated Chinese Traditional and Western Medicine. 2011;20(10):1286-8.
14. Wang M, Yao C, Wang L, Guo H, Zhu L, Ruan X, et al. Literature Analysis on the Distribution of Chronic Heart Failure Syndrome Changes in the Past 20 Years. Lishizhen Medicine and Materia Medica Research. 2015;26(11):2784-6.

15. Yang J. Literature Research on the TCM Syndrome Patterns of Chronic Heart Failure in Recent 10 Year. Continuing Medical Education. 2017;31(11):152-4.

16. Zheng X. Guiding Principles for Traditional Chinese Medicine and New Medicine on Clinical Trials. 1 ed. Beijing: China Medical Science Press (Beijing); 2002.

17. Guideline for Diagnosis and Treatment of Chronic Heart Failure. Journal of Traditional Chinese Medicine. 2014;55(14):1258-60.

18. Kawanabe T, Kamarudin ND, Ooi CY, Kobayashi F, Mi X, Sekine M, et al. Quantification of tongue colour using machine learning in Kampo medicine. European journal of integrative medicine. 2016;8(6):932-41.

19. Han S, Yang XI, Qi Q, Pan Y, Chen Y, Shen J, et al. Potential screening and early diagnosis method for cancer: Tongue diagnosis. International journal of oncology. 2016;48(6):2257-64.

20. Lee T-C, Lo L-C, Wu F-C. Traditional Chinese Medicine for Metabolic Syndrome via TCM Pattern Differentiation: Tongue Diagnosis for Predictor. Evid Based Complement Alternat Med. 2016;2016:1971295-8.

21. Tim Hideaki T. Tongue diagnosis relationship between sublingual tongue morphology in three tongue protrusion angles and menstrual clinical symptoms. Journal of Chinese Integrative Medicine. 2015;13(4):248-56.

22. WANG X, XIAO YR, Chuanyun; CAO P, LIU Y, YANG S, YIN D, et al. Correlation analysis between the distribution of tongue picture and some risk factors of heart failure in dialysis patients. 中国医药导报. 2018;15(10):110-3.

23. Xu S. Observation of tongue picture and its formation mechanism in 60 patients with heart failure with normal ejection fraction. 亚太传统医药. 2017;13(8):112-4.

24. Li D. Correspondence between petechiae per unit area of tongue surface, sublingual vein thickness and heart function grade of chronic heart failure: clinical observation of 310 cases. The Sixth Cardiovascular Academic Exchange Meeting of Integrated Traditional Chinese and Western Medicine in Jiangxi Province; Nan Chang2013.

25. Association HFGoCSoCoCM, Association CHFAoCMD, Cardiology EBoCJo. Chinese Clinical Guideline for Heart Failure Management 2018. Zhounghua Xin Xue Guan Bing Za Zhi. 2018;10(46):760-89.

26. Tao L, Shen S, Fu S, Fang H, Wang X, Das S, et al. Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice. Scientific reports. 2015;5(1):8374-.
27. Zhang H, Li S, Zhou Q, Sun Q, Shen S, Zhou Y, et al. Qiliqiangxin Attenuates Phenylephrine-Induced Cardiac Hypertrophy through Downregulation of MiR-199a-5p. Cell Physiol Biochem. 2016;38(5):1743-51.

28. Zhou Y, Fang H, Lin S, Shen S, Tao L, Xiao J, et al. Qiliqiangxin Protects Against Cardiac Ischemia-Reperfusion Injury via Activation of the mTOR Pathway. Cell Physiol Biochem. 2015;37(2):454-64.

29. Lin S, Wu X, Tao L, Bei Y, Zhang H, Zhou Y, et al. The Metabolic Effects of Traditional Chinese Medication Qiliqiangxin on H9C2 Cardiomyocytes. Cell Physiol Biochem. 2015;37(6):2246-56.

30. Zhang J, Huang M, Shen S, Wu X, Wu X, Lv P, et al. Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice. Am J Transl Res. 2017;9(12):5585-93.

31. Zhang F, Zhang Y, Li X, Zhang S, Zhu M, Du W, et al. Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association. Phytomedicine. 2018;44:220-30.

32. Li F, Wang J, Song Y, Shen D, Zhao Y, Li C, et al. Qiliqiangxin alleviates Ang II-induced CMECs apoptosis by downregulating autophagy via the ErbB2-AKT-FoxO3a axis. Life Sci. 2021;273:119239.

33. Zou Y, Lin L, Ye Y, Wei J, Zhou N, Liang Y, et al. Qiliqiangxin Inhibits the Development of Cardiac Hypertrophy, Remodeling, and Dysfunction During 4 Weeks of Pressure Overload in Mice. J CARDIOVASC PHARM. 2012;59(3):268-80.

34. Li X, Zhang J, Huang J, Ma A, Yang J, Li W, et al. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effects of Qili Qiangxin Capsules in Patients With Chronic Heart Failure. J Am Coll Cardiol. 2013;62(12):1065-72.

35. Yao W, Cheang I, Liao S, Zhou Y, Zhou F, Xu D, et al. Study protocol for a randomized controlled trial: Qiliqiangxin in heart failure: assessment of reduction in mortality (QUEST). BMC Complement Med Ther. 2020;20(1):38-.

36. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004.

37. Zhou H, Li L, Zhao H, Wang Y, Du J, Zhang P, et al. A Large-Scale, Multi-Center Urine Biomarkers Identification of Coronary Heart Disease in TCM Syndrome Differentiation. J Proteome Res. 2019;18(5):1994-2003.

38. Li X, Weil L, Jiangcheng H, Pinxian H, Guodong L, Xuebin C. Reliability and validity evaluation of TCM syndrome scale for congestive heart failure. Journal of Traditional Chinese Medicine. 2015;56(7):594-7.
39. WANG Y, REN Y, Xuebin C, Xianghe W, Gang Z, Yuanhui H, et al. Evaluation of TCM Syndrome Scales in Clinical Data of the Patients with Congestive Heart-failure. Gansu Journal of Traditional Chinese Medicine. 2015;28(12):68-71.

40. Zhang P, Fu L, Jinjin L, Liu J, Liu Y, Zhu C, et al. Formulation and Evaluation of Clinical Cross-sectional Information Collection Form in Chronic Cardiac Failure. Journal of Traditional Chinese Medicine. 2011;52(4):295-8.

41. Association ECotNHaFPCoRUoMCP. Guidelines for the rational use of drugs for heart failure (2nd edition). Chinese Journal of the Frontiers of Medical Science(Electronic Version). 2019;11(7):1-78.

42. Disease CBoCMAEBoCJoC. Chinese Journal of Cardiology 2015;42(2):98-122.

43. Christiansen TB and Lauritsen JM. (Ed.) EpiData - Comprehensive Data Management and Basic Statistical Analysis System. Odense Denmark, EpiData Association, 2010-.

44. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). EUR J HEART FAIL. 2013;15(9):1062-73.